Phase 2CompletedINTERVENTIONAL
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
ClinicalTrials.gov · NCT03007732 · Registry updated: 2025-12-05
- Condition / research focus
- Prostatic Neoplasms
- Sponsor
- David Oh
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2017-05-17. Completion: 2025-03-31 (may be estimated). Results are posted in this registry.
Products and interventions (6)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Pembrolizumab (drug) — also listed as: MK-3475, Keytruda
- SD-101 (drug) — also listed as: Toll-like receptor 9
- Leuprolide acetate (drug) — also listed as: Intermittent androgen deprivation therapy
- Abiraterone Acetate (drug) — also listed as: Intermittent androgen deprivation therapy
- Prednisone (drug) — also listed as: Intermittent androgen deprivation therapy
- Stereotactic Body Radiation Therapy (radiation) — also listed as: SBRT
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- University of California San Francisco
San Francisco, California, United States
Site recruitment: Not reported